Product
Nplate
Aliases
romiplostim
Name
Nplate
INN Name
romiplostim
FDA Approved
Yes
2 clinical trials
1 organization
4 indications
1 document
Indication
Immune Thrombocytopenic PurpuraIndication
pharmacodynamicsIndication
pharmacokineticsIndication
bioequivalenceClinical trial
Multicenter Randomized Double-blind Comparative Study of Clinical Efficacy and Safety of GNR-069 (JSC "GENERIUM", Russia) and Nplate (Amgen Europe BV, The Netherlands) in Patients With Idiopathic Thrombocytopenic PurpuraStatus: Completed, Estimated PCD: 2023-08-22
Clinical trial
Double-blind, Randomized Comparative Cross-sectional Study of Pharmacodynamics and Pharmacokinetics of Drugs GP40141, Powder for Solution for Subcutaneous Administration, 250 µg (GEROPHARM LLC, Russia) and Enplate®, Powder for Solution for Subcutaneous Administration, 250 µg (Amgen Europe B.V. ., Netherlands) in Healthy Volunteers With a Single Subcutaneous InjectionStatus: Recruiting, Estimated PCD: 2024-06-30
Document
DailyMed Label: NplateOrganization
Amgen Inc